CN103992401B - Method for preparing exenatide - Google Patents
Method for preparing exenatide Download PDFInfo
- Publication number
- CN103992401B CN103992401B CN201410179385.2A CN201410179385A CN103992401B CN 103992401 B CN103992401 B CN 103992401B CN 201410179385 A CN201410179385 A CN 201410179385A CN 103992401 B CN103992401 B CN 103992401B
- Authority
- CN
- China
- Prior art keywords
- fmoc
- exenatide
- glu
- acetonitrile
- dmf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001519 exenatide Drugs 0.000 title claims abstract description 85
- 108010011459 Exenatide Proteins 0.000 title claims abstract description 78
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 30
- 229920005989 resin Polymers 0.000 claims abstract description 65
- 239000011347 resin Substances 0.000 claims abstract description 65
- 239000012071 phase Substances 0.000 claims abstract description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 50
- 238000005859 coupling reaction Methods 0.000 claims abstract description 37
- 150000001413 amino acids Chemical class 0.000 claims abstract description 31
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000004202 carbamide Substances 0.000 claims abstract description 16
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 15
- 230000004224 protection Effects 0.000 claims abstract description 10
- 229920003180 amino resin Polymers 0.000 claims abstract description 8
- 238000000746 purification Methods 0.000 claims abstract description 8
- 238000005336 cracking Methods 0.000 claims abstract description 6
- 150000001450 anions Chemical class 0.000 claims abstract description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 84
- 238000006243 chemical reaction Methods 0.000 claims description 42
- 230000008878 coupling Effects 0.000 claims description 36
- 238000010168 coupling process Methods 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 238000010828 elution Methods 0.000 claims description 13
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 11
- 235000019257 ammonium acetate Nutrition 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 8
- 239000000052 vinegar Substances 0.000 claims description 8
- 235000021419 vinegar Nutrition 0.000 claims description 8
- 239000011260 aqueous acid Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000010612 desalination reaction Methods 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 4
- 238000005349 anion exchange Methods 0.000 claims description 4
- 229960002668 sodium chloride Drugs 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000005695 Ammonium acetate Substances 0.000 claims description 3
- 229940043376 ammonium acetate Drugs 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 14
- 239000012535 impurity Substances 0.000 abstract description 12
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 7
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 2
- 238000011049 filling Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 29
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 27
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 27
- 150000001408 amides Chemical class 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 21
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 20
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 20
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 19
- 238000010511 deprotection reaction Methods 0.000 description 17
- 150000003053 piperidines Chemical class 0.000 description 17
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000011259 mixed solution Substances 0.000 description 14
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 10
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 10
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 10
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- AHDSRXYHVZECER-UHFFFAOYSA-N 2,4,6-tris[(dimethylamino)methyl]phenol Chemical compound CN(C)CC1=CC(CN(C)C)=C(O)C(CN(C)C)=C1 AHDSRXYHVZECER-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 6
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 6
- OYXZPXVCRAAKCM-SANMLTNESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OYXZPXVCRAAKCM-SANMLTNESA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 238000003746 solid phase reaction Methods 0.000 description 6
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 5
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 5
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 5
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- GGDYAKVUZMZKRV-UHFFFAOYSA-N 2-fluoroethanol Chemical compound OCCF GGDYAKVUZMZKRV-UHFFFAOYSA-N 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- VXGGBPQPMISJCA-STQMWFEESA-N (2s)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoyl]amino]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 VXGGBPQPMISJCA-STQMWFEESA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- AKXPNRDQGXMLPW-WCCKRBBISA-N 1,3-oxazolidine (2S)-pyrrolidine-2-carboxylic acid Chemical compound O1CNCC1.N1[C@H](C(=O)O)CCC1 AKXPNRDQGXMLPW-WCCKRBBISA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- -1 alkyl phosphorus Chemical compound 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010021916 duodenin Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
Abstract
The invention relates to a method for preparing exenatide, and solves the problems that cost is high, yield is low, impurity (des-Glu＜15＞, Glu＜16＞-exenatide) content is relatively large and large-scale production cannot be realized in the prior art. The concrete steps comprise: A) taking amino resin as initial resin, employing an Fmoc solid-phase synthesis method, according to the peptide sequence of the exenatide main chain to successively couple with amino acids with Fmoc protection at N terminal and with protected side chains, wherein in the amino acid coupling reactions of the peptide sequence 15-17, a solution DMF is added with 2,2,2-trifluoroethyl alcohol accounting for 20% by volume of the solution and 1.5 mol/L of urea; and B) after peptide resin is subjected to cracking, employing a reverse-phase filling material for first purification, and employing anion resin for second purification, desalinating to enable the content of impurities des-Glu＜15＞, Glu＜16＞-exenatide to be reduced to 0.1% or less, and performing freeze drying, so as to obtain exenatide. The method is a low-cost preparation technology suitable for large-scale production of exenatide with high purity, and the technology is capable of effectively controlling the content of des-Glu＜15＞, Glu＜16＞-exenatide and does not influence the yield of exenatide.
Description
Technical field
It is a kind of synthesis with glucagon-like-peptide-1 the present invention relates to a kind of preparation method of polypeptide drug
(GLP-1) preparation method of the treatment specific drug-Exenatide of the type ii diabetes of receptor stimulating agent.
Background technology
Exenatide, English name：Exenatide, is the peptide of a straight chain 39, and structural formula is as follows：
Peptide sequence is：
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-
Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-
Pro-Pro-Pro-Ser-NH2
Exenatide is the plan duodenin developed by Amylin companies, is mainly used in treating type ii diabetes,
In No. 28 approvals of acquisition U.S. FDA of in April, 2005.Exenatide have GLP-1 receptor stimulating agents act on, molecular structure,
The aspects such as bioactivity, action target spot and immunogenicity are similar to GLP-1.The molecular structure of Exenatide is homologous with GLP-1
Up to 53 %, architectural difference shows property：（1）C-terminal has more 9 amino acid（PSSGAPPPS）, it is difficult to be degraded by endopeptidase；
（2）Second amino acid of N-terminal is glycine, will not be by dipeptidyl peptidase IV（DPP-Ⅳ）Decompose.Special molecular structure makes this
, up to 9.57 hours, injection is twice and hypoglycemia occurrence risk is small daily for patient, works as blood glucose rise for long half time of the product in blood plasma
When, this product can raise intracellular cAMP, induced insulin release；When blood sugar is reduced, the effect of its induced insulin release
Can disappear.Additionally, this product can also reduce the secretion of hyperglycemic factor in blood sugar dependence mode, and postpone gastric emptying.It is existing
In having technology US6902744, US6924264, the preparation of Exenatide using synthesis in solid state method.This kind of method is due to Ai Sai
That peptide is containing 39 peptides long of amino acid, have that technical difficulty is big, synthesis cycle is long, production cost is high, process intermediates because
Cause product purity not high for the impurity for bringing can not be purified, be unfavorable for the problems such as mass producing.
Reported in CN102942625A patents and Ser, Thr, Cys are first derived by the pseudo- proline knot of chemical conversion by liquid phase method
Structure, i.e. side chain-hydroxyl or β-sulfydryl form similar proline oxazolidine five-membered ring structures with aldehyde or ketone, then according to Fmoc
Synthesis in solid state, HPLC obtain Exenatide after purification, and purity is 95 %, yield is 36 %.This method is given birth to due to first wanting liquid phase
Into corresponding false dipeptides, therefore there are problems that synthesis cycle is long, production cost is high, be unfavorable for.
The synthesis in solid state of existing Exenatide, because Exenatide synthesis step is more, causes impurity in products species to compare
It is many, including： des-Glu15,Glu16- Exenatide and other impurity etc..Wherein relative substance des-Glu15,Glu16- Ai Saina
The amino acid sequence of peptide is as follows：
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Ala-
Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-
Pro-Ser-NH2
The impurity is one of maximum impurity of toxicity, and extremely unstable, and the presence of the impurity has a strong impact on Ai Saina
Peptide content and use safety.Therefore need to find effective method and remove it and reach the % of gold standard rank 0.1
Below.The present inventor's research finds that the means of the impurity prior art are difficult to remove, though some methods can remove part,
But removal effect is undesirable, it is difficult to reach gold standard rank while easily causing Exenatide yield reduction in itself.
The present inventor uses existing synthetic method, prepares Exenatide, finds high cost, and yield is low, and impurity is more, is unsuitable for
Industrial-scale production.Therefore, the present inventor is studied the preparation method of Exenatide, there is provided a kind of low cost,
Purity is high, is adapted to the preparation technology of the Exenatide of large-scale production, and this technique can effectively control des-Glu15,Glu16- Chinese mugwort
Fill in that peptide content and do not influence the yield problem of Exenatide.
The content of the invention
The present invention relates to a kind of method for preparing Exenatide, the high cost of prior art presence is solved, yield is low, miscellaneous
Matter des-Glu15,Glu16- Exenatide content is larger, is not suitable for the problem of large-scale production.It is an object of the invention to provide
A kind of low cost, purity are high, are adapted to the preparation technology of the Exenatide of large-scale production, and this technique can effectively control des-
Glu15,Glu16- Exenatide content does not influence the yield problem of Exenatide again.
Synthetic route of the invention is as shown in Figure 1：A）Obtained by amino resins and Fmoc-Ser (tBu)-OH couplings first
Fmoc-Ser (tBu)-resin, then by Fmoc solid-phase synthesis, is coupled with N-terminal successively according to Exenatide main chain peptide sequence
Fmoc protections and the amino acid of side chain protected, wherein, in the amino acid couplings reaction of peptide sequence 15-17, its body is added in solution D MF
The 2,2,2 tfifluoroethyl alcohol of 20 % of product and the urea of 1.5 mol/L；B）After peptide resin cracking, purifying for the first time is filled out using anti-phase
Material, second purifying uses resin anion (R.A.), and des-Glu can be made after desalination15,Glu16- Exenatide content is reduced to 0.1
Below %, freezes, and obtains Exenatide.Some conventional abbreviations have following meanings in the present invention；
Fmoc ：Fluorenylmethyloxycarbonyl
Fmoc-AA-OH ：The amino acid of fluorenylmethyloxycarbonyl protection
DIC ：N, N '-Diisopropylcarbodiimide
DCC ：N, N '-dicyclohexylcarbodiimide
PyBOP ：Hexafluorophosphoric acid BTA -1- bases-epoxide tripyrrole alkyl phosphorus
HATU ：2- (7- azos BTA)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid ester
HOBt ：1- hydroxy benzenes a pair of horses going side by side triazole
tBu ：The tert-butyl group
Trt ：Trityl
Boc ：Tertbutyloxycarbonyl
Pbf ：2,2,4,6,7- pentamethyl Dihydrobenzofuranes -5- sulfonyls
Tyr ：Tyrosine
Ile ：Isoleucine
Gln ：Glutamine
Asn ：Asparagine
Cys ：Cysteine
Pro ：Proline
Leu ：Leucine
Gly ：Glycine
Arg ：Arginine
Val ：Valine
Trp ：Tryptophan
Ala ：Alanine
Met ：Methionine
Phe ：Phenylalanine
Glu ：Glutamic acid
Lys ：Lysine
Ser ：Serine
Asp ：Aspartic acid
Thr ：Threonine
His ：Histidine
DMF ：N, N '-dimethylformamide
MeOH ：Methyl alcohol
DCM ：Dichloromethane
TFE ：2,2,2- trifluoroethanols
NMP ：1-METHYLPYRROLIDONE
DMSO ：Dimethyl sulfoxide (DMSO)
TFA ：Trifluoracetic acid
EDT ：Dithioglycol
Piperidine ：Hexahydropyridine
DIEA ：N, N '-diisopropylethylamine
For this present invention provides a kind of method for preparing Exenatide, its step is as follows：
Step 1, with amino resins as initial resin, by Fmoc solid-phase synthesis, according to Exenatide main chain peptide sequence according to
Amino acid of the secondary coupling with N-terminal Fmoc protections and side chain protected, wherein, in the amino acid couplings reaction of peptide sequence 15-17, solution
The 2,2,2 tfifluoroethyl alcohol of its volume 20 % and the urea of 1.5 mol/L are added in DMF；
Step 2, after cracking, purifying for the first time uses reverse phase filler, and second purifying uses resin anion (R.A.), can after desalination
So that des-Glu15,Glu16- Exenatide content is reduced to 0.1 below %, freezes, and obtains Exenatide.
Wherein, the solid phase synthesis process described in step 1,1）It is starting to use the amino resins of 0.10 ~ 0.35 mmol/g
Resin；2）It is 1 to use by volume ratio:Fmoc protection groups on the deprotection liquid removing amino resins of 4 piperidines and DMF composition；
3）In the presence of coupling agent system, amino resins and Fmoc-Ser (tBu)-OH couplings obtain Fmoc-Ser (tBu)-resin；
4）Repeat step 2）、3）, carrying out the coupling of amino acid successively according to Exenatide main chain peptide sequence, coupling amino acid order is：
Fmoc-Pro-OH、Fmoc-Pro-OH、Fmoc-Pro-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Ser(tBu)-OH、Fmoc-Pro-OH、Fmoc-Gly-OH、Fmoc-Gly-OH、Fmoc-Asn(Trt)-OH、Fmoc-
Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Ile-OH、Fmoc-
Phe-OH、Fmoc-Leu-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Glu(OtBu)-
OH、Fmoc-Glu(OtBu)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Met-OH、Fmoc-Gln(Trt)-OH、Fmoc-Lys
(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Leu-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、
Fmoc-Gly-OH、Boc-His(Trt)–OH.Wherein, in the amino acid couplings reaction of peptide sequence 15-17, it is added in solution D MF
2,2, the 2- trifluoroethanols and the urea of 1.5 mol/L of the % of volume 20, due to 2,2,2- trifluoroethanols can destroy beta structure stabilization
Property, mitigate the tendency of peptide interchain aggregation, the solvation degree of peptide chain can be greatly improved；And urea molecule is used to hydrogen bond
Interference effect destroys the beta sheet of peptide chain, can improve the condensation rate of Fmoc-Glu (OtBu)-OH.
Wherein, the upper amino resins is selected from Rink amide AM resins, Rink amide mbha resins, Sieber
Resin；The coupling agent system includes condensing agent and reaction dissolvent, and the condensing agent is selected from DIC/HOBt, PyBOP/HOBt/
DIEA or HATU/HOBt/DIEA；The reaction dissolvent is selected from DMF, DCM, NMP, DMSO or any combination between them.
Wherein, the purification process described in step 2, after thick peptide water dissolves, 1）Purified with C18 posts for the first time, purify bar
Part：Mobile phase is：A phases：0.1 %TFA；B phases：Acetonitrile；Gradient program is:To 60 %B in 15 %B, 60min；Detection wavelength
220 nm；Collect purpose peak cut；2）Use anion-exchange column (UniDEAE-10) second；Mobile phase：A is that buffer solution I is molten
Liquid（10 mmol/L ammonium acetate aqueous solution weak aqua ammonias adjust its pH value for 7.30 ± 0.20):Acetonitrile=90:10；B is buffer solution
II solution（The mmol/L sodium-chloride water solution acetic acid of 10 mmol/L ammonium acetates+100 adjust its pH value for 4.50 ± 0.20):
Acetonitrile=90:10；Gradient program is:To 100 %B in 100 %A, 60min；Detection wavelength is 220 nm；Purpose peak is collected to evaporate
Point；3）Desalination condition：Mobile phase：A phases：The aqueous solution of 20 mmol/L ammonium acetates:Acetonitrile=95:5；B phases：Water:Acetonitrile=95:
5；C phases：0.03 % vinegar aqueous acids:Acetonitrile=95:5；D phases：0.03 % vinegar aqueous acids:Acetonitrile=50:50；Gradient program
For：With mobile phase A Gradient elution 15 minutes, Mobile phase B Gradient elution is converted into 10 minutes, be converted into the ladders such as mobile phase C
Degree wash-out 10 minutes, is converted into mobile phase D Gradient elutions 25 minutes；The nm of Detection wavelength 220；Collect purpose peak cut；Can
So that des-Glu15,Glu16- Exenatide content is reduced to 0.1 below %, and concentrated by rotary evaporation is lyophilized to obtain Exenatide.
The method of the present invention is obtained by screening, and screening process is as follows：
1）The selection of urea concentration：
In amino acid couplings reaction in 15-17 peptide sequences, urea, the selection of urea concentration are added in solution D MF： 1.5
mol/L；2.0 mol/L
2）Add the selection of TFE volumes：
10 %；20 %
3）The selection of resin anion (R.A.) filler：
UniDEAE-10；UniQ-10.
8 kinds of experiment conditions are proposed for this：
Experiment condition 1：
1）8.14 g substitution values are taken for 0.20 mmol/g
Fmoc-Ala-Val-Arg(Pbf)-Leu-Phe-Ile-Glu(OtBu)-Trp(Boc)-Leu-Lys(Boc)-Asn
(Trt)-Gly-Gly-Pro-Ser(tBu)-Ser(tBu)-Gly-Ala-Pro-Pro-Pro-Ser(tBu)-Rink amide
AM resins (1.0 mmol) are added in solid phase reaction post, are washed with DMF 1 time, swelling 30 minutes with DCM.
2）Volume ratio is 1:The deprotection liquid of 4 piperidines and DMF composition is reacted 5 minutes, and DMF is washed 1 time, and volume ratio is 1:
The deprotection liquid of 4 piperidines and DMF composition is reacted 10 minutes, and DMF is washed 6 times.
3）Weigh 1.80 g urea to be added in the mixed solution of 16.5 ml DMF and 3.5 ml TFE, dissolve, be prepared into
The DMF/TFE mixed solutions of the urea of 1.5 mol/L.
4）Weigh 2.13 g Fmoc-Glu (OtBu)-OH（5 mmol）、0.68 g HOBt（5 mmol）Add concentration be
In the DMF/TFE mixed solutions of the urea of 1.5 mol/L, 0.8 ml DIC are added under ice-water bath（5 mmol）After activation, add
In the above-mentioned reaction column equipped with resin, react 2 hours at room temperature.
5）Repeat 2）-4）Twice, similarity condition is coupled two Fmoc-Glu (OtBu)-OH again.
6）Remaining amino acid is coupled successively, and coupling amino acid order is：Fmoc-Met-OH、Fmoc-Gln(Trt)-OH、
Fmoc-Lys(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Leu-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Ser
(tBu)-OH、Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu
(OtBu)-OH、Fmoc-Gly-OH、Boc-His(Trt)–OH.Coupling is finished, and is washed with DMF 3 times, and DCM is washed 3 times, and MeOH is washed
Wash 3 times, DCM is washed 3 times, MeOH is washed 3 times, is drained and is obtained 11.82 g Exenatide Rink amide AM resins.
7）Above-mentioned resin is added in the three neck round bottom flask of 250 mL, by TFA:Thioanisole:Methyl phenyl ethers anisole:EDT=
90:5:3:The 2 volume ratio configuration mL of lysate 100, during lysate added into above-mentioned resin, room temperature reaction 2 hours, filtering is used
Resin after a small amount of TFA washings cracking 3 times, merging filtrate, concentration, precipitation 1 is small during the liquid after concentration is added into ice ether
When, centrifugation, absolute ether centrifuge washing 6 times, vacuum drying obtains the thick g of peptide 4.20 of Exenatide.The % of HPLC purity 63.57,
The % of synthesis yield 82.
8）After the thick peptide of above-mentioned Exenatide is weighed with 4 L water dissolves, purified with C18 posts for the first time, purification condition：Mobile phase
For：A phases：0.1 %TFA；B phases：Acetonitrile；Gradient program is:To 60 %B in 15 %B, 60 min；The nm of Detection wavelength 220；Receive
Collection purpose peak cut.
9）Use anion-exchange column (UniDEAE-10) second；Mobile phase：A is buffer solution I solution（10 mmol/L vinegar
Sour aqueous ammonium weak aqua ammonia adjust its pH value for 7.30 ± 0.20):Acetonitrile=90:10；B is the solution of buffer solution II（10
The mmol/L sodium-chloride water solution acetic acid of mmol/L ammonium acetates+100 adjust its pH value for 4.50 ± 0.20):Acetonitrile=90:10；
Gradient program is：To 100 %B in 100 %A, 60 min；Detection wavelength is 220 nm；Collect purpose peak cut.
10）Desalination condition：
Mobile phase：A phases：The aqueous solution of 20 mmol/L ammonium acetates:Acetonitrile=95:5；
B phases：Water:Acetonitrile=95:5；
C phases：0.03 % vinegar aqueous acids:Acetonitrile=95:5；
D phases：0.03 % vinegar aqueous acids:Acetonitrile=50:50；
Gradient program is：With mobile phase A Gradient elution 15 minutes, Mobile phase B Gradient elution is converted into 10 minutes,
It is converted into mobile phase C Gradient elutions 10 minutes, is converted into mobile phase D Gradient elutions 25 minutes；
The nm of Detection wavelength 220；Collect purpose peak cut；Concentrated by rotary evaporation, it is lyophilized to obtain Exenatide acetate fine peptide 1.92
The % of g, HPLC purity 99.89, purifies the % of yield 56, the % of total recovery 46.
Experiment condition 2-8, experimental implementation is as shown in experiment condition 1, and each experiment condition and experimental result are as follows：
Result above shows that the purification effect of experiment condition 7 is optimal.
Compared to the prior art the method for the present invention has obvious advantage, and relevant contrast experiment is as follows：
The beneficial effects of the invention are as follows：The present inventor is studied the preparation method of Exenatide, there is provided a kind of
Low cost, purity are high, are adapted to the preparation technology of the Exenatide of large-scale production, and this technique can effectively control des-Glu15,
Glu16- Exenatide content does not influence the yield of Exenatide again.
Brief description of the drawings
Fig. 1 synthetic routes of the invention；
The HPLC spectrograms of the thick peptide of Fig. 2 Exenatides；
The HPLC spectrograms of Fig. 3 Exenatide fine peptides；
The HPLC spectrograms of Fig. 4 Exenatide control samples；
The Exenatide fine peptide mass spectrogram of Fig. 5 embodiments nine.
Specific embodiment
The present invention is further illustrated by the following examples.
Embodiment one：Substitution value is the synthesis of Fmoc-Ser (tBu)-Rink amide AM resins of 0.20 mmol/g
Weigh the Rink amide AM resins that 5.00 g substitution values are 0.20 mmol/g（1 mmol）, it is added to solid phase
In reaction column, washed with DMF 1 time, with DCM swellable resins 30 minutes after, it is 1 to use volume ratio:4 piperidines and DMF composition
Deprotection liquid is reacted 5 minutes, and DMF is washed 1 time, and it is 1 to use volume ratio:The deprotection liquid of 4 piperidines and DMF composition reacts 10 points
Clock, DMF is washed 6 times, weighs 1.92 g Fmoc-Ser (tBu)-OH（5 mmol）With 0.68 g HOBt（5 mmol）Add body
Product is than being 1:1 DCM and DMF mixed solutions, add 0.8 ml DIC under ice-water bath（5 mmol）Above-mentioned being equipped with is added after activation
In the reaction column of resin, react 2 hours, washed with DMF 3 times, DCM is washed 3 times, MeOH is washed 3 times, DCM is washed 3 times, MeOH
Washing 3 times, 5.15 g Fmoc- Ser (tBu)-Rink amide AM resins are obtained after drying.
Embodiment two：Substitution value is the conjunction of Fmoc-Ser (tBu)-Rink amide MBHA resins of 0.20 mmol/g
Into
Weigh the Rink amide MBHA resins that 5.00 g substitution values are 0.20 mmol/g（1 mmol）, it is added to solid
In phase reaction post, washed with DMF 1 time, with DCM swellable resins 30 minutes after, it is 1 to use volume ratio:4 piperidines and DMF composition
Deprotection liquid react 5 minutes, DMF wash 1 time, it is 1 to use volume ratio:The deprotection liquid reaction 10 of 4 piperidines and DMF composition
Minute, DMF is washed 6 times, weighs 1.92 g Fmoc-Ser (tBu)-OH（5 mmol）With 0.68 g HOBt（5 mmol）Add
Volume ratio is 1:1 DCM and DMF mixed solutions, add 0.8 ml DIC under ice-water bath（5 mmol）Above-mentioned dress is added after activation
Have in the reaction column of resin, react 2 hours, washed with DMF 3 times, DCM is washed 3 times, MeOH is washed 3 times, DCM is washed 3 times,
MeOH is washed 3 times, and 5.14 g Fmoc-Ser (tBu)-Rink amide MBHA resins are obtained after drying.
Embodiment three：Substitution value is the synthesis of Fmoc-Ser (tBu)-Sieber resins of 0.20 mmol/g
Weigh the Rink amide Sieber resins that 5.00 g substitution values are 0.20 mmol/g（1 mmol）, it is added to
In solid phase reaction post, washed with DMF 1 time, with DCM swellable resins 30 minutes after, it is 1 to use volume ratio:4 piperidines and DMF groups
Into deprotection liquid react 5 minutes, DMF wash 1 time, it is 1 to use volume ratio:The deprotection liquid reaction of 4 piperidines and DMF composition
10 minutes, DMF was washed 6 times, weighs 1.92 g Fmoc-Ser (tBu)-OH（5 mmol）With 0.68 g HOBt（5 mmol）Plus
It is 1 to enter volume ratio:1 DCM and DMF mixed solutions, add 0.8 ml DIC under ice-water bath（5 mmol）Added after activation above-mentioned
In reaction column equipped with resin, react 2 hours, washed with DMF 3 times, DCM is washed 3 times, MeOH is washed 3 times, DCM is washed 3 times,
MeOH is washed 3 times, and 5.15 g Fmoc- Ser (tBu)-Sieber resins are obtained after drying.
Example IV：The preparation of Exenatide Rink amide AM resins
Weigh Fmoc-Ser (tBu)-Rink amide AM resins that 5.15 g substitution values are 0.20 mmol/g（1
mmol）, add in solid phase reaction post, washed with DMF 1 time, with DCM swelling Fmoc-Ser (tBu)-Rink amide AM resins
After 30 minutes, it is 1 to use volume ratio:The deprotection liquid of 4 piperidines and DMF composition is reacted 5 minutes, and DMF is washed 1 time, using body
Product is than being 1:The deprotection liquid of 4 piperidines and DMF composition is reacted 10 minutes, and DMF is washed 6 times, weighs 1.69 g Fmoc-Pro-
OH（5 mmol）、0.68 g HOBt（5 mmol）It is 1 to add volume ratio:1 DCM and DMF mixed solutions, add under ice-water bath
0.8 ml DIC（5 mmol）After activation, add in the above-mentioned reaction column equipped with resin, react 2 hours at room temperature, with ninhydrin
Method detection judges reaction end, if resin water white transparency, then it represents that reaction is complete；Resin develops the color, then it represents that reaction is incomplete,
Need to react again 1 hour, this criterion judges reaction end suitable for subsequent amino-acid coupling with ninhydrin method detection.
The step of repeating above-mentioned removing Fmoc protections and add corresponding amino acid couplings, according to Exenatide main chain peptide sequence,
Be sequentially completed Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Ser (tBu)-OH,
Fmoc-Ser(tBu)-OH、Fmoc-Pro-OH、Fmoc-Gly-OH、Fmoc-Gly-OH、Fmoc-Asn(Trt)-OH、Fmoc-
Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Ile-OH、Fmoc-
Phe-OH、Fmoc-Leu-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Glu(OtBu)-
OH、Fmoc-Glu(OtBu)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Met-OH、Fmoc-Gln(Trt)-OH、Fmoc-Lys
(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Leu-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、
Fmoc-Gly-OH、Boc-His(Trt)–OH。
Wherein, 1）In the amino acid couplings reaction of peptide sequence 15-17, the 2 of its volume 20%, 2,2- trifluoros are added in solution D MF
The urea of ethanol and 1.5 mol/L；2）Solvent is changed to when Fmoc-Leu-OH and Fmoc-Phe-OH is coupled：It is 1 from volume ratio:
4 DMSO and DMF mixed solutions；3）Coupling reagent is changed to when Fmoc-Asp (OtBu)-OH is coupled：PyBOP/HOBt/DIEA；4）
Coupling reagent is changed to when Fmoc-Val-OH is coupled：HATU/HOBt/DIEA.Coupling is finished, and is washed with DMF 3 times, DCM washings 3
Secondary, MeOH is washed 3 times, and DCM is washed 3 times, and MeOH is washed 3 times, is drained and is obtained 11.84g Exenatide Rink amide AM trees
Fat.
Embodiment five：The preparation of Exenatide Rink amide MBHA resins
Weigh Fmoc-Ser (tBu)-Rink amide MBHA resins that 5.14 g substitution values are 0.20 mmol/g（1
mmol）, add in solid phase reaction post, washed with DMF 1 time, with DCM swelling Fmoc-Ser (tBu)-Rink amide MBHA trees
After fat 30 minutes, it is 1 to use volume ratio:The deprotection liquid of 4 piperidines and DMF composition is reacted 5 minutes, and DMF is washed 1 time, is used
Volume ratio is 1:The deprotection liquid of 4 piperidines and DMF composition is reacted 10 minutes, and DMF is washed 6 times, weighs 1.69 g Fmoc-
Pro-OH（5 mmol）、0.68 g HOBt（5 mmol）It is 1 to add volume ratio:1 DCM and DMF mixed solutions, under ice-water bath
Add 0.8 ml DIC（5 mmol）After activation, in the above-mentioned reaction column equipped with resin of addition, after reacting 2 hours at room temperature, with
Ninhydrin method detection judges reaction end, if resin water white transparency, then it represents that reaction is complete；Resin develops the color, then it represents that reaction
Not exclusively, it is necessary to react again 1 hour, this criterion judges reaction suitable for subsequent amino-acid coupling with ninhydrin method detection
Terminal.
The step of repeating above-mentioned removing Fmoc protections and add corresponding amino acid couplings, according to Exenatide main chain peptide sequence,
It is sequentially completed：Fmoc-Pro-OH、Fmoc-Pro-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Ser(tBu)-OH、Fmoc-Pro-OH、Fmoc-Gly-OH、Fmoc-Gly-OH、Fmoc-Asn(Trt)-OH、Fmoc-
Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Ile-OH、Fmoc-
Phe-OH、Fmoc-Leu-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Glu(OtBu)-
OH、Fmoc-Glu(OtBu)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Met-OH、Fmoc-Gln(Trt)-OH、Fmoc-Lys
(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Leu-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、
Fmoc-Gly-OH、Boc-His(Trt)–OH。
Wherein, 1）In the amino acid couplings reaction of peptide sequence 15-17,2, the 2,2- tri- of its volume 20 % are added in solution D MF
The urea of fluoroethanol and 1.5 mol/L；2）Solvent is changed to when Fmoc-Leu-OH and Fmoc-Phe-OH is coupled：It is from volume ratio
1:4 DMSO and DMF mixed solutions；3）Coupling reagent is changed to when Fmoc-Asp (OtBu)-OH is coupled：PyBOP/HOBt/DIEA；
4）Coupling reagent is changed to when Fmoc-Val-OH is coupled：HATU/HOBt/DIEA.Coupling is finished, and is washed with DMF 3 times, DCM washings 3
Secondary, MeOH is washed 3 times, and DCM is washed 3 times, and MeOH is washed 3 times, is drained and is obtained 11.86g Exenatide Rink amide AM trees
Fat.
Embodiment six：The preparation of Exenatide Sieber resins
Weigh Fmoc-Ser (tBu)-Rink amide MBHA resins that 5.15 g substitution values are 0.20 mmol/g（1
mmol）, add in solid phase reaction post, washed with DMF 1 time, with DCM swelling Fmoc-Ser (tBu)-Rink amide MBHA trees
After fat 30 minutes, it is 1 to use volume ratio:The deprotection liquid of 4 piperidines and DMF composition is reacted 5 minutes, and DMF is washed 1 time, is used
Volume ratio is 1:The deprotection liquid of 4 piperidines and DMF composition is reacted 10 minutes, and DMF is washed 6 times, weighs 1.69 g Fmoc-
Pro-OH（5 mmol）、0.68 g HOBt（5 mmol）It is 1 to add volume ratio:1 DCM and DMF mixed solutions, under ice-water bath
Add 0.8 ml DIC（5 mmol）After activation, in the above-mentioned reaction column equipped with resin of addition, after reacting 2 hours at room temperature, with
Ninhydrin method detection judges reaction end, if resin water white transparency, then it represents that reaction is complete；Resin develops the color, then it represents that reaction
Not exclusively, it is necessary to react again 1 hour, this criterion judges reaction suitable for subsequent amino-acid coupling with ninhydrin method detection
Terminal.
The step of repeating above-mentioned removing Fmoc protections and add corresponding amino acid couplings, according to Exenatide main chain peptide sequence,
It is sequentially completed：Fmoc-Pro-OH、Fmoc-Pro-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Ser(tBu)-OH、Fmoc-Pro-OH、Fmoc-Gly-OH、Fmoc-Gly-OH、Fmoc-Asn(Trt)-OH、Fmoc-
Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Ile-OH、Fmoc-
Phe-OH、Fmoc-Leu-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Glu(OtBu)-
OH、Fmoc-Glu(OtBu)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Met-OH、Fmoc-Gln(Trt)-OH、Fmoc-Lys
(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Leu-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、
Fmoc-Gly-OH、Boc-His(Trt)–OH。
Wherein, 1）In the amino acid couplings reaction of peptide sequence 15-17,2, the 2,2- tri- of its volume 20 % are added in solution D MF
The urea of fluoroethanol and 1.5 mol/L；2）Solvent is changed to when Fmoc-Leu-OH and Fmoc-Phe-OH is coupled：It is from volume ratio
1:4 DMSO and DMF mixed solutions；3）Coupling reagent is changed to when Fmoc-Asp (OtBu)-OH is coupled：PyBOP/HOBt/DIEA；
4）Coupling reagent is changed to when Fmoc-Val-OH is coupled：HATU/HOBt/DIEA.Coupling is finished, and is washed with DMF 3 times, DCM washings 3
Secondary, MeOH is washed 3 times, and DCM is washed 3 times, and MeOH is washed 3 times, is drained and is obtained 11.86 g Exenatide Sieber resins.
Embodiment seven：The prepare with scale of Exenatide Rink amide AM resins
Weigh Fmoc-Ser (tBu)-Rink amide AM resins that 5152.50 g substitution values are 0.20 mmol/g（1
mol）, add in solid phase reaction post, washed with DMF 1 time, with DCM swelling Fmoc-Ser (tBu)-Rink amide AM resins 30
After minute, it is 1 to use volume ratio:The deprotection liquid of 4 piperidines and DMF composition is reacted 5 minutes, and DMF is washed 1 time, using volume
Than being 1:The deprotection liquid of 4 piperidines and DMF composition is reacted 10 minutes, and DMF is washed 6 times, weighs 1690.21 g Fmoc-Pro-
OH（5 mol）、680.40 g HOBt（5 mol）It is 1 to add volume ratio:1 DCM and DMF mixed solutions, add under ice-water bath
800 ml DIC（5mol）After activation, in the above-mentioned reaction column equipped with resin of addition, after reacting 2 hours at room temperature, with ninhydrin
Method detection judges reaction end, if resin water white transparency, then it represents that reaction is complete；Resin develops the color, then it represents that reaction is incomplete,
Need to react again 1 hour, this criterion judges reaction end suitable for subsequent amino-acid coupling with ninhydrin method detection.
The step of repeating above-mentioned removing Fmoc protections and add corresponding amino acid couplings, according to Exenatide main chain peptide sequence,
It is sequentially completed：Fmoc-Pro-OH、Fmoc-Pro-OH、Fmoc-Ala-OH、Fmoc-Gly-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Ser(tBu)-OH、Fmoc-Pro-OH、Fmoc-Gly-OH、Fmoc-Gly-OH、Fmoc-Asn(Trt)-OH、Fmoc-
Lys(Boc)-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Ile-OH、Fmoc-
Phe-OH、Fmoc-Leu-OH、Fmoc-Arg(Pbf)-OH、Fmoc-Val-OH、Fmoc-Ala-OH、Fmoc-Glu(OtBu)-
OH、Fmoc-Glu(OtBu)-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Met-OH、Fmoc-Gln(Trt)-OH、Fmoc-Lys
(Boc)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Leu-OH、Fmoc-Asp(OtBu)-OH、Fmoc-Ser(tBu)-OH、
Fmoc-Thr(tBu)-OH、Fmoc-Phe-OH、Fmoc-Thr(tBu)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、
Fmoc-Gly-OH、Boc-His(Trt)–OH。
Wherein, 1）In the amino acid couplings reaction of peptide sequence 15-17,2, the 2,2- tri- of its volume 20 % are added in solution D MF
The urea of fluoroethanol and 1.5 mol/L；2）Solvent is changed to when Fmoc-Leu-OH and Fmoc-Phe-OH is coupled：It is from volume ratio
1:4 DMSO and DMF mixed solutions；3）Coupling reagent is changed to when Fmoc-Asp (OtBu)-OH is coupled：PyBOP/HOBt/DIEA；
4）Coupling reagent is changed to when Fmoc-Val-OH is coupled：HATU/HOBt/DIEA.Coupling is finished, and is washed with DMF 3 times, DCM washings 3
Secondary, MeOH is washed 3 times, and DCM is washed 3 times, and MeOH is washed 3 times, is drained and is obtained 11910.05 g Exenatide Rink amide
AM resins.
Embodiment eight：The preparation of the thick peptide of Exenatide
Above-mentioned 100.00 g Exenatides Rink amide AM resins are added in the three neck round bottom flask of 2000 mL,
By TFA:Thioanisole:Methyl phenyl ethers anisole:EDT=90:5:3:The 2 volume ratio configuration mL of lysate 1000, lysate is added above-mentioned
In resin, room temperature reaction 2 hours, filtering, the resin after washing cracking with a small amount of TFA 3 times, merging filtrate, concentration, after concentration
Liquid be added in ice ether and precipitate 1 hour, centrifugation, absolute ether centrifuge washing 6 times, vacuum drying obtains Exenatide
The thick g of peptide 35.21.The % of HPLC purity 63.57, the % of synthesis yield 82.
Embodiment nine：The preparation of Exenatide fine peptide acetate
After the above-mentioned thick peptide of 35.21 g Exenatides is weighed with 35 L water dissolves, purified with C18 posts for the first time, purification condition：
Mobile phase is：A phases：0.1 %TFA；B phases：Acetonitrile；Gradient program is：To 60%B in 15 %B, 60min；Detection wavelength 220
nm；Collect purpose peak cut.Use anion-exchange column (UniDEAE-10) second；Mobile phase：A is buffer solution I solution（10
Mmol/L ammonium acetate aqueous solution weak aqua ammonias adjust its pH value for 7.30 ± 0.20):Acetonitrile=90:10;B is that buffer solution II is molten
Liquid（The mmol/L sodium-chloride water solution acetic acid of 10 mmol/L ammonium acetates+100 adjust its pH value for 4.50 ± 0.20):Acetonitrile=
90:10；Gradient program is：To 100 %B in 100 %A, 60 min；Detection wavelength is 220 nm；Collect purpose peak cut.It is de-
The condition of salt：Mobile phase：A phases：The aqueous solution of 20 mmol/L ammonium acetates:Acetonitrile=95:5；B phases：Water:Acetonitrile=95:5；C phases：
0.03 % vinegar aqueous acids:Acetonitrile=95:5；D phases：0.03 % vinegar aqueous acids:Acetonitrile=50:50；Gradient program is：With
Mobile phase A Gradient elution 15 minutes, is converted into Mobile phase B Gradient elution 10 minutes, is converted into mobile phase C constant gradients and washes
It is de- 10 minutes, it is converted into mobile phase D Gradient elutions 25 minutes；The nm of Detection wavelength 220；Collect purpose peak cut；Revolving is dense
Contracting, it is lyophilized to obtain Exenatide acetate fine peptide 16.10 g, the % of HPLC purity 99.89, purify the % of total recovery 56, total recovery 46
%。des-Glu15, Glu16- Exenatide content is 0.05 %.
Embodiment ten：Impurity des-Glu15,Glu16The assay of-Exenatide
des-Glu15,Glu16The content of-Exenatide=Exenatide reference substance content × des-Glu15,Glu16- Ai Sai
That peptide peak area × Exenatide reference substance concentration × correction factor/（The Exenatide reference substance peak area × thick peptide of Exenatide
Concentration) × 100 %=92.15 % × 0.042 × 1.0 × 1.00/（79.406×1.0）×100 %=0.05 %
Note：Exenatide reference substance is consistent with sample size with the testing conditions of Exenatide fine peptide, all for：25 μl.des-
Glu15,Glu16Correction factor=1.00 of-Exenatide.
Exenatide reference substance concentration：1.0 mg/ml
Exenatide reference substance peak area：79.406 mAU*min （Fig. 3）
Exenatide reference substance content：92.15 %
The thick peptide configuration concentration of Exenatide：1.0 mg/ml
Impurity des-Glu in Exenatide fine peptide15,Glu16- Exenatide peak area：0.042 mAU*min
Claims (1)
1. a kind of method for preparing Exenatide, it is characterised in that the described method comprises the following steps：
Step 1, it is even successively according to Exenatide main chain peptide sequence by Fmoc solid-phase synthesis with amino resins as initial resin
Amino acid of the connection with N-terminal Fmoc protections and side chain protected, wherein, in the amino acid couplings reaction of peptide sequence 15-17, solution D MF
The urea of the middle 2,2,2 tfifluoroethyl alcohol and 1.5mol/L for adding its volume 20%；
Step 2, after peptide resin cracking, 1) purify for the first time using the purifying of C18 posts, purification condition：Mobile phase is：A phases：0.1%
TFA；B phases：Acetonitrile；Gradient program is：To 60%B in 15%B, 60min；Detection wavelength 220nm；Collect purpose peak cut；2)
Second purifying uses resin anion (R.A.), uses UniDEAE-10 anion-exchange columns；Mobile phase：A is 10mmol/L ammonium acetate water
Solution weak aqua ammonia adjusts the buffer solution that its pH value is 7.30 ± 0.20:Acetonitrile=90:10；B be 10mmol/L ammonium acetates+
100mmol/L sodium-chloride water solution acetic acid adjusts the buffer solution that its pH value is 4.50 ± 0.20:Acetonitrile=90:10；Gradient journey
Sequence is：To 100%B in 100%A, 60min；Detection wavelength is 220nm；Collect purpose peak cut；3) desalination condition：Mobile phase：
A phases：The aqueous solution of 20mmol/L ammonium acetates:Acetonitrile=95:5；B phases：Water:Acetonitrile=95:5；C phases：0.03% acetic acid it is water-soluble
Liquid:Acetonitrile=95:5；D phases：0.03% vinegar aqueous acid:Acetonitrile=50:50；Gradient program is：Washed with mobile phase A constant gradient
It is de- 15 minutes, it is converted into Mobile phase B Gradient elution 10 minutes, it is converted into mobile phase C Gradient elutions 10 minutes, it is converted into stream
Dynamic phase D Gradient elutions 25 minutes；Detection wavelength 220nm；Collect purpose peak cut；It is lyophilized, obtain Exenatide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410179385.2A CN103992401B (en) | 2014-04-30 | 2014-04-30 | Method for preparing exenatide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410179385.2A CN103992401B (en) | 2014-04-30 | 2014-04-30 | Method for preparing exenatide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103992401A CN103992401A (en) | 2014-08-20 |
| CN103992401B true CN103992401B (en) | 2017-05-17 |
Family
ID=51306764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410179385.2A Active CN103992401B (en) | 2014-04-30 | 2014-04-30 | Method for preparing exenatide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103992401B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109929011B (en) * | 2019-05-06 | 2021-04-06 | 上海上药第一生化药业有限公司 | Method for refining vasopressin [5-Asp ] impurity |
| CN112608376B (en) * | 2020-12-17 | 2022-05-20 | 温州医科大学慈溪生物医药研究院 | Preparation method of active peptide Apelin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101538323A (en) * | 2009-01-13 | 2009-09-23 | 深圳市翰宇药业有限公司 | Method for purifying exenatide |
| CN102942625A (en) * | 2012-11-30 | 2013-02-27 | 南京工业大学 | Exenatide solid-phase synthesis method |
-
2014
- 2014-04-30 CN CN201410179385.2A patent/CN103992401B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101538323A (en) * | 2009-01-13 | 2009-09-23 | 深圳市翰宇药业有限公司 | Method for purifying exenatide |
| CN102942625A (en) * | 2012-11-30 | 2013-02-27 | 南京工业大学 | Exenatide solid-phase synthesis method |
Non-Patent Citations (2)
| Title |
|---|
| 多肽"困难序列"的合成研究进展;姜和 等;《重庆理工大学学报（自然科学）》;20110531;第25卷(第5期);第3.7、3.8节 * |
| 降糖药艾塞那肽和利拉鲁肽的固相合成及艾塞那肽的药效学评价;张许;《中国优秀硕士学位论文全文数据库》;20130715;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103992401A (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109311961B (en) | A kind of synthetic method of semaglutide | |
| CN102875665B (en) | Method for synthesizing liraglutide | |
| CN104017064B (en) | A kind of method preparing teriparatide | |
| CN103980358B (en) | A kind of method preparing Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37] | |
| CN103497245B (en) | Method for synthesizing thymalfasin | |
| CN106146648B (en) | Synthetic method of parathyroid hormone analogue | |
| US20080287650A1 (en) | High purity peptides | |
| CN110294800B (en) | Preparation method of somaglutide | |
| CN104650219B (en) | The method that fragment condensation prepares Liraglutide | |
| CN104004083B (en) | A kind of method synthesizing Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37] | |
| CN103224558B (en) | A kind of preparation method of Exenatide | |
| CN103864918A (en) | Solid-phase synthesis method for liraglutide | |
| CN108047329A (en) | A kind of preparation method of A Bapa peptides | |
| CN110372785A (en) | A kind of synthetic method of Suo Malu peptide | |
| CN106478805B (en) | Preparation method of GLP-1 derivative | |
| CN106167514A (en) | The synthesis of a kind of Linaclotide and purification process | |
| CN113880936B (en) | Solid-phase synthesis method of abamectin | |
| CN101747426A (en) | Method for synthesizing pramlintide | |
| CN104788546A (en) | Preparation method of linear peptides containing 24 amino acid residues | |
| CN106554391B (en) | Method for synthesizing marine biological peptide Xen2174 | |
| CN106632655B (en) | Preparation method of exenatide and product thereof | |
| CN104177491B (en) | A kind of preparation method of Tesamorelin | |
| CN1552728B (en) | Synthetic method of somatostatin | |
| CN108059667B (en) | A kind of solid phase synthesis process of Lanreotide | |
| CN103992401B (en) | Method for preparing exenatide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 310018, Hangzhou Economic Development Zone, Zhejiang, No. 6, No. 452 Street Applicant after: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 310018, Hangzhou Economic Development Zone, Zhejiang, No. 6, No. 452 Street Applicant before: Hangzhou Sinopep Pharmaceutical Inc. |
|
| COR | Change of bibliographic data | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 310018, Hangzhou Economic Development Zone, Zhejiang, No. 6, No. 452 Street Applicant after: HANGZHOU ANUO BIOLOGICAL MEDICINE TECHNOLOGY CO., LTD. Address before: 310018, Hangzhou Economic Development Zone, Zhejiang, No. 6, No. 452 Street Applicant before: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Lu Yang Inventor after: Yang Donghui Inventor after: Chen Xiaohang Inventor after: Zhou Liang Inventor after: Cheng Li Inventor before: Lu Yang Inventor before: Yang Donghui Inventor before: Chen Xiaohang Inventor before: Zhou Liang |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |